Trailing-twelve-month (TTM) revenue is $422.58 Million with a year-over-year growth of +8.57%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $104,163,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $106,154,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-05 |
| Q1 FY2026Period ended 2026-03-31 | $104,100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $108,164,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $422,581,000 |
Current P/S: $635,223,494 market capitalization ÷ $422,581,000 TTM revenue = 1.50x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:00:07.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $108.16M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:01:47.721Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|
| Financial Service | $18M | $22M | $29M | $60M | $100M |
| Health Care | N/A | N/A | N/A | $11M | $10M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|
| Europe | $42M | $55M | N/A | N/A | N/A |
| NETHERLANDS | N/A | N/A | $12M | $10M | N/A |
$422.58M
$422.58 Million
+8.57%
vs. $389.22M a year ago (TTM)
+24.16%
5 Year compound annual growth rate
1 Year
+8.57%
3 Year
+9.81%
5 Year
+24.16%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $411.83M | +$61.26M | +17.47% |
| 2024 | $350.57M | +$37.66M | +12.04% |
| 2023 | $312.91M | +$2.43M | +0.78% |
| 2022 | $310.48M | +$99.20M | +46.95% |
| 2021 | $211.28M | +$100.00M | +89.86% |
| 2020 |
TTM Growth
+8.57%
3-Year CAGR
+9.81%
5-Year CAGR
+24.16%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 27 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:01:47.721Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| Manufactured Product, Other |
|---|
| $43M |
| $61M |
| $43M |
| $40M |
| $43M |
| Product and Service, Other | $21M | $29M | $40M | $30M | $30M |
|---|
| Retail | $62M | $100M | $103M | $114M | $121M |
|---|
| Technology, Media, And Telecom | $68M | $98M | $99M | $95M | $107M |
|---|
| North America |
|---|
| $169M |
| $255M |
| N/A |
| N/A |
| N/A |
| Other Countries Not Separately Disclosed | N/A | N/A | $31M | $38M | $63M |
|---|
| POLAND | N/A | N/A | N/A | N/A | $14M |
|---|
| UNITED STATES | N/A | N/A | $238M | $278M | $289M |
|---|
| $111.28M |
| ($7.04M) |
| (5.95%) |
| 2019 | $118.33M | +$26.46M | +28.80% |
| 2018 | $91.86M | +$21.18M | +29.97% |
